More Paradigm Biopharmaceuticals Ltd. news
Paradigm Biopharmaceuticals Ltd.ASX: PAR

Trading Halt

Dec 4, 2024 at 10:07 PM EST · Issued by Paradigm Biopharmaceuticals Ltd.

Filed with ASX · Dec 4, 2024 at 10:07 PM EST

On 6ix: 6ix.com/news/trading-halt-422

Paradigm Biopharmaceuticals Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Paradigm Biopharmaceuticals Ltd. on 6ix

Earlier from Paradigm Biopharmaceuticals

  • Paradigm to Proceed with Phase 3 Knee OA TrialNov 27, 2024
  • Response to ASX Price QueryNov 25, 2024
  • 2024 Chairman Address and AGM PresentationNov 18, 2024
  • Phase 3 Protocol Submission to US FDAOct 30, 2024
  • Paradigm Investor UpdateOct 20, 2024

Later from Paradigm Biopharmaceuticals

  • Successful Completion of $16M Placement for Phase 3Dec 8, 2024
  • PAR Capital Raising PresentationDec 8, 2024
  • Paradigm Receives $6.3m R&D Tax RefundJan 23, 2025
  • Quarterly Activities/Appendix 4C Cash Flow ReportJan 30, 2025
  • PAR Selects Advanced Clinical as CRO for Phase 3Jan 30, 2025
All Paradigm Biopharmaceuticals news releases↗

Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.

Follow Paradigm Biopharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer